 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioVaxys Technology Corp. is a clinical stage biotechnology company. It engages in developing viral and oncology vaccine platforms, as well as immuno-diagnostics. The firm is advancing a SARS-CoV-2 vaccine based on its haptenized viral protein technology and is preparing for a clinical trial of its haptenized autologous cell vaccine used in combination with anti-PD1 and anti-PDL-1 checkpoint inhibitors that will initially be developed for Stage III/Stage IV ovarian cancer. The company was founded by James Christopher Passin, Kenneth E. Kovan and David Berd on April 25, 2018 and is headquartered in Etobicoke, Canada.

Watchers	460
52-Wk Low	$0.0114
52-Wk High	$0.20

Market Cap	$2.1M
Volume (M)	8,301.00
52-Wk High	$0.20
52-Wk Low	$0.0114

Current Price	$0.0145
Prev Close	$0.0145
Open	$0.0165
Dividend Yield	0.00%
50-Day Moving Average	$0.0157
Beta	0.67
Avg. Volume	64,586.35
PE Ratio	-0.18

52-Week High	$0.20
52-Week Low	$0.0114
Market Capitalization	$2.1M
EPS	-$0.0809
Price to Book	3.24
Revenue Per Employee	N/A
Enterprise Value/EBITDA	-1.44

BVAXF Biovaxys Technology Corp

About

Feed

News

Fundamentals